Bristol to move forward with phase 3 trial of combo in first-line renal cancer Bristol-Myers said it plans to move forward with a Phase 3 study of the combination of nivolumab and Yervoy in the first line setting with the objective of improving overall survival for renal cell cancers. The company also said that based upon "very promising data" from its 003 study that the company has accelerated the start of its Phase 3 program study 025, which is now completely enrolled. Comments made earlier on its ASCO highlights investor meeting.
News For BMY From The Last 14 Days
Check below for free stories on BMY the last two weeks.